Fintel reports that on June 2, 2023, Needham reiterated coverage of Atricure (NASDAQ:ATRC) with a Buy recommendation.
Analyst Price Forecast Suggests 33.24% Upside
As of June 2, 2023, the average one-year price target for Atricure is 61.00. The forecasts range from a low of 50.50 to a high of $82.95. The average price target represents an increase of 33.24% from its latest reported closing price of 45.78.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Atricure is 388MM, an increase of 10.97%. The projected annual non-GAAP EPS is -0.85.
What is the Fund Sentiment?
There are 505 funds or institutions reporting positions in Atricure. This is an increase of 12 owner(s) or 2.43% in the last quarter. Average portfolio weight of all funds dedicated to ATRC is 0.19%, a decrease of 13.71%. Total shares owned by institutions decreased in the last three months by 3.01% to 57,846K shares. 
The put/call ratio of ATRC is 0.86, indicating a bullish outlook.
What are Other Shareholders Doing?
Alliancebernstein holds 3,124K shares representing 6.61% ownership of the company. In it's prior filing, the firm reported owning 3,566K shares, representing a decrease of 14.16%. The firm decreased its portfolio allocation in ATRC by 34.08% over the last quarter.
Champlain Investment Partners holds 1,892K shares representing 4.01% ownership of the company. In it's prior filing, the firm reported owning 1,940K shares, representing a decrease of 2.52%. The firm increased its portfolio allocation in ATRC by 89,332.25% over the last quarter.
AOFAX - Alger Small Cap Focus Fund holds 1,551K shares representing 3.28% ownership of the company. In it's prior filing, the firm reported owning 1,735K shares, representing a decrease of 11.89%. The firm increased its portfolio allocation in ATRC by 4.67% over the last quarter.
Fred Alger Management holds 1,511K shares representing 3.20% ownership of the company. In it's prior filing, the firm reported owning 1,755K shares, representing a decrease of 16.15%. The firm decreased its portfolio allocation in ATRC by 25.46% over the last quarter.
Wellington Management Group Llp holds 1,483K shares representing 3.14% ownership of the company. In it's prior filing, the firm reported owning 1,609K shares, representing a decrease of 8.51%. The firm decreased its portfolio allocation in ATRC by 87.99% over the last quarter.
Atricure Background Information
(This description is provided by the company.)
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator ® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
Key filings for this company:
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
